330 related articles for article (PubMed ID: 15540952)
1. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
[TBL] [Abstract][Full Text] [Related]
2. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
3. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
[TBL] [Abstract][Full Text] [Related]
5. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
6. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
[TBL] [Abstract][Full Text] [Related]
7. Variable effects of chronic subcutaneous administration of rotenone on striatal histology.
Zhu C; Vourc'h P; Fernagut PO; Fleming SM; Lacan S; Dicarlo CD; Seaman RL; Chesselet MF
J Comp Neurol; 2004 Oct; 478(4):418-26. PubMed ID: 15384065
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
Sherer TB; Kim JH; Betarbet R; Greenamyre JT
Exp Neurol; 2003 Jan; 179(1):9-16. PubMed ID: 12504863
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity.
Luo C; Rajput AH; Akhtar S; Rajput A
Int J Mol Med; 2007 Mar; 19(3):517-21. PubMed ID: 17273802
[TBL] [Abstract][Full Text] [Related]
10. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease.
Alam M; Schmidt WJ
Physiol Behav; 2004 Dec; 83(3):395-400. PubMed ID: 15581661
[TBL] [Abstract][Full Text] [Related]
13. Anomalous structure-activity relationships of 13-homo-13-oxarotenoids and 13-homo-13-oxadehyrorotenoids.
Fang N; Rowlands JC; Casida JE
Chem Res Toxicol; 1997 Aug; 10(8):853-8. PubMed ID: 9282833
[TBL] [Abstract][Full Text] [Related]
14. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice.
Li X; Yin J; Cheng CM; Sun JL; Li Z; Wu YL
Chin Med J (Engl); 2005 Aug; 118(16):1357-61. PubMed ID: 16157030
[TBL] [Abstract][Full Text] [Related]
15. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.
Ravenstijn PG; Merlini M; Hameetman M; Murray TK; Ward MA; Lewis H; Ball G; Mottart C; de Ville de Goyet C; Lemarchand T; van Belle K; O'Neill MJ; Danhof M; de Lange EC
J Pharmacol Toxicol Methods; 2008; 57(2):114-30. PubMed ID: 18155613
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
17. Sleep disturbances in the rotenone animal model of Parkinson disease.
García-García F; Ponce S; Brown R; Cussen V; Krueger JM
Brain Res; 2005 May; 1042(2):160-8. PubMed ID: 15854587
[TBL] [Abstract][Full Text] [Related]
18. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
19. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture.
Radad K; Gille G; Rausch WD
Toxicol In Vitro; 2008 Feb; 22(1):68-74. PubMed ID: 17923380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
